Blue Chipped: What happened to Cochlear (ASX: COH)?

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

(Sorry for the late send, I was tossing up between about ten different ear puns for the email subject line)

Every so often, the market takes one of its untouchables, the blue chips, the set-and-forgets, the “safe” stocks your grandpa owns… and throws them down the stairs.

Yesterday it was Cochlear's (ASX: COH) turn.

Down 40% in a single session. Worst day on record. 

Worst day, in fact, since the company was listed in 1995. 

$4 billion in shareholder value, gone before morning tea.

Cochlear sells hearing implants and was, for much of a decade, side by side with CSL as one of the largest healthcare companies on the ASX.

(It still sits in the top ten, capped at $6.51 billion, but a far cry from where it was at $22 billion just two years ago)

Its lead product is a surgically implanted device that bypasses damaged parts of the inner ear to restore hearing for the severely and profoundly deaf. 

Cochlear has roughly 60% of the global market share and a franchise built on earning recurring revenue from selling sound processor upgrades to a massive installed base.

With the massive drop yesterday, I had a lot of text come through from people saying that “the growth story is gone”.

So, what happened?

Yesterday, Cochlear published its net profit guidance for the year.

August 2025 → FY26 net profit guidance: $435M -$460M

Feb 2026 → FY26 net profit guidance: lower end of $435M - $460M

Yesterday → FY26 net profit guidance: $290M - $330M

I think what made things worse is how much has changed in just two months.

Here is the net profit guidance given in mid-Feb:

For profit guidance to be downgraded by over $140M in just two months, is remarkable.

Something doesn’t quite add up. 

I don’t buy the “soft demand from the Middle East narrative”; there appears to be something a bit more structural at play here.

I’ve been reading through the commentary, and I think the article from The Australian is on point.

Importantly, the Big Beautiful Bill removed health insurance for a number of US citizens and cut Medicaid, affecting referral volumes:

So the question for the investment community…

Is this downgrade just a blip?

OR, are there structural challenges that affect the longer-term growth outlook for the company?

Right now, trading at a share price of ~$100 and a NPAT guidance of $310M, you’re paying ~21x earnings.

This is also the company’s lowest share price since 2016, when it reported $189M in sales (a 53x earnings multiple).

Cochlear has traded around that 40-50x earnings multiple for the better part of a decade.

So this is definitely a value downgrade on future earnings.

Is it “cheap”? 

I’d like to see a bit more information about why the earnings were downgraded so much so quickly.

This will provide better answers on whether there is something structurally wrong or an earnings blip.

As my stock trader friend says… if there are back-to-back downgrades, that’s a sell.

And right now, I’m not looking to catch the falling knife.

Let’s dive in…

InteliCare (ASX: ICR) signs a $200K, 3-year agreement with Warrigal Care to deploy its AI-driven monitoring platform across 65 retirement villas. (ICR)

🪑 That's a few deals now for ICR in the last few weeks. Nice work.

Cannabis stocks in the US are all up as the US Federal Government is expected to re-classify federal cannabis as early as tomorrow. (Capital Brief)

🪑 The ASX-listed pot stocks that are best placed to take advantage of this are those that are leveraging cannabis as a medicine:

Read my coverage of the decision: Trump floats new cannabis rules: Weeding out the good from the bad 

Clarity Pharmaceuticals (ASX: CU6) Managing Director Michelle Parker sold 360,000 shares at ~$3 per share to settle a tax liability arising from the exercise of share options. (CU6)

🪑  No matter how big the tax bill, it’s never great to see an MD sell stock in the company.

Nyrada (ASX: NYR) activates the first site for its Phase IIa trial on myocardial injury in patients suffering from a heart attack. (NYR)

🪑  Nice, looking forward to this one.

Arovella Therapeutics (ASX: ALA) rejects the 249D notice, claiming that it was invalid (ALA), and now the shareholder has withdrawn the 249D notice. (ALA)

🪑 🍿 I reckon there is more to play out with this story.

I covered the initial 249D notice here: When Shares Become the Vote: The 249D-ilemma 

Tetratherix (ASX: TTX) quarterly update, with highlights and progress across all six programs. (TTX)

🪑 Reading through the management commentary from CEO Will Knox, it's clear this has been a very good quarter for TTX.

The main highlight is the agreement with Superpower Health and the emergence of the Tetramatrix platform for nasal delivery of GLP-1s and Peptides.

But also, TTX made progress across its other platforms, including:

$19M still in the bank, burning about $2.5M per quarter, with lots of activity to come.

TTX is in very good shape.

Disclosure: I own 16,250 escrowed TTX shares and also initiated coverage on TTX this quarter: My First Armchair Pick: Tetratherix (ASX: TTX)

Radiopharm Theranostics (ASX: RAD) published its quarterly report. (RAD)

🪑 As a notorious cash burner, I wanted to see what this quarter looked like. 

~$15M in in outflows from operating activities (with the majority towards staff and R&D). $19M still in the bank. 

That’s the price of running multiple clinical trials at the same time.

Paradigm Biopharmaceuticals (ASX: PAR) requests a trading halt pending an announcement about a capital raising. (PAR)

See you all tomorrow,

The Armchair Analyst

🪑